CA2370741A1 - Procede pour detecter et tuer les cellule du cancer epithelial - Google Patents
Procede pour detecter et tuer les cellule du cancer epithelial Download PDFInfo
- Publication number
- CA2370741A1 CA2370741A1 CA002370741A CA2370741A CA2370741A1 CA 2370741 A1 CA2370741 A1 CA 2370741A1 CA 002370741 A CA002370741 A CA 002370741A CA 2370741 A CA2370741 A CA 2370741A CA 2370741 A1 CA2370741 A1 CA 2370741A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- agent
- marking agent
- cancer cells
- mitochondrial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000009030 Carcinoma Diseases 0.000 title claims abstract description 26
- 230000002147 killing effect Effects 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 89
- 239000003550 marker Substances 0.000 claims abstract description 51
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 34
- 201000011510 cancer Diseases 0.000 claims abstract description 31
- 125000002091 cationic group Chemical group 0.000 claims abstract description 31
- 210000003470 mitochondria Anatomy 0.000 claims abstract description 27
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 27
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 13
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 12
- 239000007795 chemical reaction product Substances 0.000 claims abstract description 6
- 238000002405 diagnostic procedure Methods 0.000 claims abstract description 5
- 229940044683 chemotherapy drug Drugs 0.000 claims abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 230000007246 mechanism Effects 0.000 claims description 7
- 210000000981 epithelium Anatomy 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 210000001700 mitochondrial membrane Anatomy 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- QTWZICCBKBYHDM-UHFFFAOYSA-N leucomethylene blue Chemical compound C1=C(N(C)C)C=C2SC3=CC(N(C)C)=CC=C3NC2=C1 QTWZICCBKBYHDM-UHFFFAOYSA-N 0.000 claims 1
- 239000003139 biocide Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000975 dye Substances 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 12
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 11
- 230000014759 maintenance of location Effects 0.000 description 8
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 229950003937 tolonium Drugs 0.000 description 7
- 230000000717 retained effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 230000005880 cancer cell killing Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- -1 e.g. Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000001016 thiazine dye Substances 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 230000025608 mitochondrion localization Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000007614 solvation Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- IOFXEUZPIIUQAG-UHFFFAOYSA-M Tiemonium iodide Chemical compound [I-].C=1C=CSC=1C(O)(C=1C=CC=CC=1)CC[N+]1(C)CCOCC1 IOFXEUZPIIUQAG-UHFFFAOYSA-M 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- SRAVWPVICTXESG-UHFFFAOYSA-N [4-(2,4-diamino-5-methylphenyl)iminocyclohexa-2,5-dien-1-ylidene]-dimethylazanium;chloride Chemical compound [Cl-].C1=C(N)C(C)=CC(N=C2C=CC(C=C2)=[N+](C)C)=C1N SRAVWPVICTXESG-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940023020 acriflavine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- PGWTYMLATMNCCZ-UHFFFAOYSA-M azure A Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 PGWTYMLATMNCCZ-UHFFFAOYSA-M 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 230000009841 epithelial lesion Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229950008849 furazolium chloride Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- FMPJXUZSXKJUQI-UHFFFAOYSA-N hydron;3-(5-nitrofuran-2-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;chloride Chemical compound Cl.O1C([N+](=O)[O-])=CC=C1C1=CSC2=NCCN12 FMPJXUZSXKJUQI-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- RNUAEUWXRHCGKX-UHFFFAOYSA-N oxythiamine chloride Chemical compound [Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)NC1=O RNUAEUWXRHCGKX-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- XFDQJKDGGOEYPI-UHFFFAOYSA-O peonidin Chemical compound C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 XFDQJKDGGOEYPI-UHFFFAOYSA-O 0.000 description 1
- 229930015721 peonidin Natural products 0.000 description 1
- 235000006404 peonidin Nutrition 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- INCIMLINXXICKS-UHFFFAOYSA-M pyronin Y Chemical compound [Cl-].C1=CC(=[N+](C)C)C=C2OC3=CC(N(C)C)=CC=C3C=C21 INCIMLINXXICKS-UHFFFAOYSA-M 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- SOUHUMACVWVDME-UHFFFAOYSA-N safranin O Chemical compound [Cl-].C12=CC(N)=CC=C2N=C2C=CC(N)=CC2=[N+]1C1=CC=CC=C1 SOUHUMACVWVDME-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 150000003510 tertiary aliphatic amines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000004897 thiazines Chemical class 0.000 description 1
- 229960005128 tiemonium iodide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Procédé diagnostique pour détecter les cellules du cancer épithélial par le marquage sélectif des mitochondries des cellules cancéreuses; le procédé consiste à administrer à l'épithélium un agent de marquage mitochondrial supravital cationique. La destruction sélective des cellules cancéreuses épithéliales en présence de cellules normales est effectuée par l'administration d'un agent de marquage mitochondrial supravital cationique. L'agent de destruction peut aussi comprendre un produit de réaction de l'agent de marquage et un médicament chimiothérapeutique contre le cancer ou être mélangé à ce médicament.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/005387 WO2001064110A1 (fr) | 2000-02-28 | 2000-02-28 | Methode de detection et d'elimination de cellules cancereuses epitheliales |
| USPCT/US00/05387 | 2000-02-28 | ||
| PCT/US2001/006318 WO2001064255A1 (fr) | 2000-02-28 | 2001-02-27 | Procede pour detecter et tuer les cellule du cancer epithelial |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2370741A1 true CA2370741A1 (fr) | 2001-09-07 |
Family
ID=21741108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002370741A Abandoned CA2370741A1 (fr) | 2000-02-28 | 2001-02-27 | Procede pour detecter et tuer les cellule du cancer epithelial |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1214101A4 (fr) |
| JP (1) | JP2003525044A (fr) |
| KR (2) | KR100907122B1 (fr) |
| CN (1) | CN100544770C (fr) |
| AU (2) | AU2000237154A1 (fr) |
| BR (1) | BR0104747A (fr) |
| CA (1) | CA2370741A1 (fr) |
| CZ (1) | CZ20013861A3 (fr) |
| IL (1) | IL146141A0 (fr) |
| MX (1) | MXPA01010886A (fr) |
| NO (1) | NO20015242L (fr) |
| NZ (1) | NZ515202A (fr) |
| RU (1) | RU2226404C2 (fr) |
| WO (2) | WO2001064110A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001064110A1 (fr) * | 2000-02-28 | 2001-09-07 | Zila, Inc. | Methode de detection et d'elimination de cellules cancereuses epitheliales |
| BR0013636A (pt) * | 2000-06-30 | 2005-01-11 | Zila Inc | Uso de uma composição de rodamina para identificação e delineação do tecido epitelial canceroso |
| IL149330A0 (en) * | 2000-09-26 | 2002-11-10 | Zila Inc | Method for early prediction of the onset of invasive cancer |
| JP2005514040A (ja) * | 2001-12-14 | 2005-05-19 | ズィラ、インコーポレイテッド | 癌の予後および診断のための光指向性分子分析 |
| US6890571B2 (en) | 2002-05-14 | 2005-05-10 | National Starch And Chemical Investment Holding Corporation | Slowly digestible starch product |
| US7081261B2 (en) * | 2002-05-14 | 2006-07-25 | National Starch And Chemical Investment Holding Corporation | Resistant starch prepared by isoamylase debranching of low amylose starch |
| US6929817B2 (en) | 2002-05-14 | 2005-08-16 | National Starch & Chemical Investment Holding Corporation | Slowly digestible starch product |
| CN1302815C (zh) * | 2002-06-04 | 2007-03-07 | 日拉生物技术公司 | 甲苯胺蓝o药物及其在异常组织的体内染色和化疗中的用途 |
| AU2004324049A1 (en) * | 2004-09-30 | 2006-04-20 | Zila Biotechnology, Inc. | Light-directed method for detecting and aiding further evaluation of abnormal mucosal tissue |
| JP5855326B2 (ja) | 2005-01-06 | 2016-02-09 | ノヴォ ノルディスク アー／エス | 抗ｋｉｒ組み合わせ治療および方法 |
| MY189329A (en) | 2009-07-15 | 2022-02-04 | Nutricia Nv | Mixture of non-digestible oligosaccharides for stimulating the immune system |
| CN103185713B (zh) * | 2011-12-29 | 2015-12-09 | 闫文广 | 用于上皮组织肿瘤细胞的检测剂组合物及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321251A (en) * | 1979-12-19 | 1982-03-23 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse |
| US5194373A (en) * | 1985-06-06 | 1993-03-16 | Thomas Jefferson University | Method of determining endothelial cell coverage of a prosthetic surface |
| US4816395A (en) * | 1985-12-19 | 1989-03-28 | Peralta Cancer Research Institute | Method for predicting chemosensitivity of anti-cancer drugs |
| ES2133143T3 (es) * | 1991-10-31 | 1999-09-01 | Zila Inc | Composicion de tincion biologica, procedimiento de preparacion y procedimiento de utilizacion para la deteccion del cancer epitelial. |
| ATE253380T1 (de) * | 1996-01-16 | 2003-11-15 | Zila Inc | Verfahren und mittel zur in-vivo erkennung von mundhöhlenkrebs und von präkanzerösen zuständen |
| US6086852A (en) * | 1997-11-13 | 2000-07-11 | Zila, Inc. | In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue |
| AU2593600A (en) * | 1998-12-23 | 2000-07-12 | G.D. Searle & Co. | Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia |
| WO2001064110A1 (fr) * | 2000-02-28 | 2001-09-07 | Zila, Inc. | Methode de detection et d'elimination de cellules cancereuses epitheliales |
| EP1301164A4 (fr) * | 2000-07-20 | 2005-10-05 | Zila Inc | Methode de diagnostic amelioree pour la detection de tissu epithelial dysplastique |
| IL149330A0 (en) * | 2000-09-26 | 2002-11-10 | Zila Inc | Method for early prediction of the onset of invasive cancer |
-
2000
- 2000-02-28 WO PCT/US2000/005387 patent/WO2001064110A1/fr active Application Filing
- 2000-02-28 AU AU2000237154A patent/AU2000237154A1/en not_active Abandoned
-
2001
- 2001-02-27 NZ NZ515202A patent/NZ515202A/en unknown
- 2001-02-27 EP EP01916271A patent/EP1214101A4/fr not_active Ceased
- 2001-02-27 WO PCT/US2001/006318 patent/WO2001064255A1/fr active Application Filing
- 2001-02-27 KR KR1020017013731A patent/KR100907122B1/ko not_active IP Right Cessation
- 2001-02-27 AU AU43316/01A patent/AU785489B2/en not_active Ceased
- 2001-02-27 CA CA002370741A patent/CA2370741A1/fr not_active Abandoned
- 2001-02-27 CN CNB018006604A patent/CN100544770C/zh not_active Expired - Fee Related
- 2001-02-27 CZ CZ20013861A patent/CZ20013861A3/cs unknown
- 2001-02-27 KR KR1020087020377A patent/KR20080080681A/ko not_active Application Discontinuation
- 2001-02-27 IL IL14614101A patent/IL146141A0/xx unknown
- 2001-02-27 JP JP2001563152A patent/JP2003525044A/ja active Pending
- 2001-02-27 BR BR0104747-7A patent/BR0104747A/pt not_active Application Discontinuation
- 2001-02-27 RU RU2001132076/15A patent/RU2226404C2/ru not_active IP Right Cessation
- 2001-02-27 MX MXPA01010886A patent/MXPA01010886A/es active IP Right Grant
- 2001-10-26 NO NO20015242A patent/NO20015242L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU4331601A (en) | 2001-09-12 |
| EP1214101A1 (fr) | 2002-06-19 |
| RU2226404C2 (ru) | 2004-04-10 |
| CN1365288A (zh) | 2002-08-21 |
| MXPA01010886A (es) | 2002-05-06 |
| KR20080080681A (ko) | 2008-09-04 |
| JP2003525044A (ja) | 2003-08-26 |
| KR100907122B1 (ko) | 2009-07-09 |
| KR20020000222A (ko) | 2002-01-05 |
| WO2001064255A1 (fr) | 2001-09-07 |
| EP1214101A4 (fr) | 2005-04-13 |
| CN100544770C (zh) | 2009-09-30 |
| NO20015242L (no) | 2001-11-29 |
| NO20015242D0 (no) | 2001-10-26 |
| AU785489B2 (en) | 2007-11-15 |
| AU2000237154A1 (en) | 2001-09-12 |
| NZ515202A (en) | 2003-05-30 |
| WO2001064110A1 (fr) | 2001-09-07 |
| CZ20013861A3 (cs) | 2002-08-14 |
| BR0104747A (pt) | 2002-09-17 |
| IL146141A0 (en) | 2002-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Han et al. | A ratiometric fluorescent probe for imaging and quantifying anti-apoptotic effects of GSH under temperature stress | |
| Leonidova et al. | Photo-induced uncaging of a specific Re (I) organometallic complex in living cells | |
| AU785489B2 (en) | Method for detecting and killing epithelial cancer cells | |
| Basu et al. | Biological Evaluation of the NIR‐Emissive Ruby Analogue [Cr (ddpd) 2][BF4] 3 as a Photodynamic Therapy Photosensitizer | |
| FI74036C (fi) | Faergaemneskomposition foer histologiska undersoekningar. | |
| Wawi et al. | Peptide Vectors Carry Pyrene to Cell Organelles Allowing Real‐Time Quantification of Free Radicals in Mitochondria by Time‐Resolved Fluorescence Microscopy | |
| US6649144B1 (en) | Method for detecting and killing epithelial cancer cells | |
| Chan et al. | Photodynamic activity of a glucoconjugated silicon (IV) phthalocyanine on human colon adenocarcinoma | |
| US20030017158A1 (en) | Method for detecting and killing epithelial cancer cells | |
| Vuong et al. | Hypericin incorporation and localization in fixed HeLa cells for various conditions of fixation and incubation | |
| Gieseler et al. | Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding | |
| Stearns et al. | Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets. | |
| Lundvall et al. | Hepatic fluorescence in porphyria cutanea tarda studied in fine needle aspiration biopsy smears | |
| CA2120002C (fr) | Methode de cytodiagnostic utilisant l'alstonine comme marqueur selectif et trousse de diagnostic contenant ledit marqueur | |
| Horobin | Xanthenes | |
| BRPI0612367A2 (pt) | solução para a marcação de células ou de tecidos, kit, método de marcação ex vivo de células ou de um tecido, uso de uma solução e método de diagnóstico in vitro de um cáncer ou de uma displasia | |
| RU2713151C1 (ru) | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения | |
| Bertolesi et al. | Cytochemical application of tris (2, 2'-bipyridine) ruthenium (II): fluorescence reaction with sulfated polyanions of mast cell granules. | |
| Winkelman et al. | Staining with tetraphenylporphinesulfonate in vivo | |
| Varmazyad et al. | N-alkyl triphenylvinylpyridinium conjugated dihydroartemisinin perturbs mitochondrial functions resulting in enhanced cancer versus normal cell toxicity | |
| US20110077230A1 (en) | Copper organocomplexes, use thereof as antitumor means and for protecting healthy tissue from ionizing radiation | |
| BISHOP et al. | Differentiation of the acrosome in living mammalian spermatozoa and spermatids by fluorescence microscopy | |
| Hösli et al. | Monoamine-containing neurones in cultures of rat brain stem | |
| Fioretti et al. | Monitoring of hematoporphyrin injected in humans and clinical prospects of its use in gynecologic oncology | |
| Schmid et al. | Differential uptake of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea and doxorubicin by Lewis lung carcinoma and Ridgway osteogenic sarcoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |